<DOC>
	<DOCNO>NCT02828657</DOCNO>
	<brief_summary>A prospective , multicenter , open-label , post-approval study safety effectiveness ORBERA™ adjunct weight reduction obese adult ( 22 year age old ) Body Mass Index ( BMI ) ≥ 30 kg/m2 BMI ≤ 40 kg/m2</brief_summary>
	<brief_title>ORBERA™ Post-Approval Study</brief_title>
	<detailed_description>FDA post-approval study design demonstrate safety effectiveness ORBERA™ adjunct weight reduction obese adult ( 22 year age old ) Body Mass Index ( BMI ) ≥ 30 kg/m2 BMI ≤ 40 kg/m2 . Behavioral modification program conjunction endoscopic placement single ORBERA™ Intragastric Balloon , fill saline inflation volume 400cc 700cc , 26 week follow endoscopic ORBERA™ removal . Outcomes include mean percent Total Body Weight Loss ( % TBWL ) , change weight , device procedure-related AEs SAEs : gastric ulcer , esophageal injury , placement removal relate SAEs , early device removal , balloon deflation .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<criteria>1 . 22 year age old ; 2 . BMI ≥ 30 kg/m2 ≤ 40 kg/m2 ; 3 . Have history obesity ( BMI ≥ 30 kg/m2 ) ≥ 2 year ; 4 . Have fail conservative weightreduction alternative , supervise diet , exercise , behavioral modification program ; 5 . Be willing commit longterm supervise diet behavior modification program design increase possibility longterm weight loss maintenance ; 6 . Be able follow requirement outline protocol , include comply visit schedule ; 7 . Be able provide write informed consent ; 1 . Presence one intragastric balloon time ; 2 . Prior gastrointestinal surgery ; 3 . Has inflammatory disease gastrointestinal ( GI ) tract include esophagitis , gastric ulceration , duodenal ulceration , cancer specific inflammation Crohn 's disease ; 4 . Has gastrointestinal bleeding condition esophageal gastric varix , congenital acquire intestinal telangiectasis , congenital anomaly GI tract atresias stenosis ; 5 . Has large hiatal hernia hernia &gt; 5 cm hernia ≤ 5 cm associate severe intractable gastroesophageal reflux symptom ; 6 . Has structural abnormality esophagus pharynx stricture diverticulum could impede passage delivery catheter and/or endoscope ; 7 . Has achalasia severe motility disorder may pose safety risk removal device ; 8 . Has gastric mass ; 9 . Has severe coagulopathy ; 10 . Has hepatic insufficiency cirrhosis ; 11 . Has medical condition would permit elective endoscopy , poor general health history and/or symptom severe renal , hepatic , cardiac , and/or pulmonary disease ; 12 . Has serious uncontrolled psychiatric illness disorder could compromise subject understand compliance followup visit removal device 6 month ; 13 . Alcoholism drug addiction ; 14 . Unable unwilling take prescribed proton pump inhibitor medication duration device placement ; 15 . Unwilling participate establish medicallysupervised diet behavior modification program , routine medical followup ; 16 . Taking daily dose aspirin , antiinflammatory agent , anticoagulant gastric irritant routinely medical supervision ; 17 . Females pregnant , nursing , plan pregnancy within next year ; 18 . Known , suspect , allergy material contain ORBERA™ ; 19 . Participation previous ( within 60 day study day 1 ) ongoing clinical trial current past usage ( within 60 day study day 1 ) investigational drug device , use intragastric balloon prior study ; 20 . Genetically caused obesity ; 21 . Prior bariatric surgery consider bariatric surgery study ; 22 . Concomitant use , unwillingness avoid use , weight loss medication , weight loss supplement , weight loss herbal preparation ; 23 . Has condition situation Investigator 's opinion may put subject significant risk may interfere significantly subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ORBERA</keyword>
</DOC>